BRAF and neoplasm: The 2022 WHO classification also introduced new categories of high-grade non-anaplastic malignant tumors with intermediate prognosis, including poorly differentiated thyroid carcinoma, presenting >3 mitoses per 2 mm2 and/or tumor necrosis and aberrant RAS signaling related to FTC; differentiated high-grade carcinoma, which has tumor necrosis and/or ≥5 mitoses per 2 mm2 as specific features, and, in the majority of cases, BRAF V600E-driven as it displays the cytoarchitectural properties of PTC [8,9,32].